Publication: Household Demand for Preventive HIV/AIDS Vaccines in Thailand : Do Husbands' and Wives' Preferences Differ?
No Thumbnail Available
Published
2008
ISSN
1098-3015
Date
2012-03-30
Editor(s)
Abstract
Objectives: The aims of this study were to estimate household demand in the general population of Thailand for a (hypothetical) preventive HIV vaccine; to determine whether spouses in the same household would purchase the same number of vaccines for household members and have the same demand function; to determine whether spouses would allocate vaccines to the same household members; and to estimate household and per capita average willingness to pay (WTP) for an HIV vaccine price. Methods: The data come from a national contingent valuation survey of 2524 residents (aged 18-20 years) of 1235 households in Thailand during the period 2000 to 2001. In a subsample of 561 households, both head of household and spouse completed independent (separate) interviews. Respondents were asked whether they would purchase an HIV vaccine for themselves and for other household members if one were available at a specified price. Results: For the full sample, average household WTP for the vaccine was substantial (US$610 at 50% vaccine effectiveness, US$671 at 95% effectiveness); the average per capita WTP for household members was US$220 at 50% effectiveness and US$242 at 95% effectiveness. Although spouses reported that they would purchase the same total number of vaccines, and had essentially the same demand functions, at lower vaccine prices wives were significantly more likely than husbands to allocate vaccines to their daughters than to sons. Conclusions: Because wives are more likely to allocate vaccines to daughters, vaccination programs aimed at women and girls might have different outcomes than programs directed at males or at all potential adults without regard to sex.
Link to Data Set
Associated content
Other publications in this report series
Journal
Journal Volume
Journal Issue
Citations
- Cited 23 times in Scopus (view citations)
Collections
Related items
Showing items related by metadata.
Publication The Potential Demand for an HIV/AIDS Vaccine in Brazil(World Bank, Washington, DC, 2002-12)This study assesses the potential demand by the public sector for a preventive HIV/AIDS vaccine in Brazil and the costs of alternative strategies for a vaccination program. Brazil has a mature AIDS epidemic: the percent of the population living with HIV or AIDS (about 0.6 percent of adults) is not as high as in other severely affected developing countries, but infection rates in specific risk groups in the population are very high and HIV has spread beyond these groups into the general population of low-risk individuals. Preventive HIV/AIDS vaccines are still in the testing stage. The characteristics of the first vaccines developed, in terms of their efficacy, duration of effectiveness, ease of administration, and price, are still unknown. But the potential benefits of such a vaccine in Brazil would be high. The study reviews the cost and impact of HIV/AIDS in Brazil, in terms of disease and economic burden, as a proxy for the benefits of an HIV/AIDS vaccine. The epidemiology of AIDS and Brazil's experience with immunization coverage with other vaccines are used to assess the number of vaccines, delivery strategies, and possible costs of an HIV/AIDS immunization program in Brazil, assuming the availability of a 100 percent effective AIDS vaccine that lasts a lifetime under different pricing and dosing assumptions. A low-cost, highly effective vaccine would likely be affordable to an upper-middle-income country like Brazil and yield large benefits from a policy of universal, publicly subsidized immunization. But if prices are higher and the impact less favorable, the costs and effects would have to be compared with other AIDS prevention programs or other health interventions. Both political and economic considerations will likely figure into public policy on HIV/AIDS vaccination, when such a vaccine is developed.Publication Water for the Urban Poor : Water Markets, Household Demand, and Service Preferences in Kenya(World Bank, Washington, DC, 2005-01)Access to safe water supply has been one of the top priorities in developing countries over the past three to four decades, and billions of dollars have been invested in pursuit of the goal of universal service. And yet the general consensus at the 2002 United Nations World Summit on Sustainable Development was that the current reality-as well as the situation expected in the near future-are far from that goal (The Economist Sept. 7-13, 2002). In fact, recent reports emphasize that the world is facing a serious water crisis and that water access and service delivery in the developing world need to be improved dramatically and urgently, especially if we are to make gains in the fight against poverty, hunger, and disease (United Nations 2003). World leaders not only agree that water is an important part of the core development agenda but have also committed to ambitious targets for expanding access to water services. At the U.N. Millennium Summit in 2000 and subsequently at the Johannesburg Earth Summit in 2002, world leaders agreed to a set of time-bound and measurable development targets-widely known as the Millennium Development Goals for 2015-which include a commitment to halve the proportion of people without access to safe drinking water.Publication A Cost–Benefit Analysis of Cholera Vaccination Programs in Beira, Mozambique(World Bank, 2009-06-30)Economic and epidemiological data collected in Beira, Mozambique, are used to conduct this first social cost–benefit analysis for cholera vaccination in Sub-Saharan Africa. The analysis compares the net economic benefits of three immunization strategies with and without user fees: school-based vaccination for school children only (age 5–14), school-based vaccination for all children (age 1–14), and a mass vaccination campaign for all people older than one year. All options assume the use of a low-cost new-generation oral cholera vaccine. The analysis incorporates the latest knowledge of vaccine effectiveness, including new evidence on the positive externality associated with the resulting herd protection (both protection of unvaccinated individuals and enhanced protection among vaccinated individuals arising from vaccination of a portion of the population). It also uses field data for incidence, benefits (private willingness to pay, public cost of illness), and costs (production, shipping, delivery, private travel costs). Taking herd protection into account has important economic implications. For a wide variety of parameters values, vaccination programs in Beira pass a cost–benefit test. Small school-based programs with and without user fees are very likely to provide net benefits. A mass vaccination campaign without user fees would result in the greatest reduction in the disease burden, but the social costs would likely outweigh the benefits, and such a program would require substantial public sector investment. As user fees increase, mass vaccination becomes much more attractive, and the reduction in disease burden remains above 70 percent at relatively low user fees.Publication The Value of Preventing Malaria in Tembien, Ethiopia(World Bank, Washington, DC, 2000-01)The authors measure the monetary value households place on preventing malaria in Tembien, Tigray Region, Ethiopia. They estimate a household demand function for a hypothetical malaria vaccine and compute the value of preventing malaria as the households maximum willingness to pay to provide vaccines for all family members. They contrast willingness to pay with the traditional costs of illness (medical costs and time lost because of malaria). Their results indicate that the value of preventing malaria with vaccines is about US$36 a household a year, or about 15 percent of imputed annual household income. This is, on average, about two or three times the expected household cost of illness. Despite the great benefits from preventing malaria, the fact that vaccine demand is price inelastic suggests that it will be difficult to achieve significant market penetration unless the vaccine is subsidized. The authors obtain similar results for insecticide-treated bed nets. Their estimates of household demand functions for bed nets suggest that at a price that might permit cost recovery (US$6 a bed net), only a third of the population of a 200-person village would sleep under bed nets.Publication Education and HIV/AIDS : A Sourcebook of HIV/AIDS Prevention Programs(Washington, DC, 2004)This sourcebook aims to support efforts by countries to strengthen the role of the education sector in the prevention of HIV/AIDS. It was developed in response to numerous requests for a simple forum to help countries share their practical experiences of designing and implementing programs that are targeted at school-age children. The sourcebook seeks to fulfill this role by providing concise summaries of programs, using a standard format that highlights the main elements of the programs and makes it easier to compare the programs with each other. All the programs are summarized in section two, which allows those seeking advice on program design to browse through the various options and identify those that might reward further study. The full program reports for each country are given in section three. Each program report follows the same format, so the reader can more easily find those aspects of the program that are of specific interest. The consistent design also allows for ease of comparison between programs. There are four main sections within each full program report. Part A gives an overview of the program, describing the rationale, the aims and objectives, the target audience, the components, and the main approaches. Part B describes the process from the initial needs assessment, through the development of materials and training, to the practical details of implementation. There is an attempt made to estimate unit costs, but these should be seen only as indicative, because the number of beneficiaries is often uncertain and because costs in newly implemented programs may be artificially high. Part C provides an assessment and comprises lessons learned. This section begins with comments from implementers on the challenges faced and the lessons learned, followed in a few cases by a description of any formal evaluation of the program. The final part explores the extent to which the program complies with a set of benchmarks that, on the basis of expert opinion, contribute to an effective program. Part D gives details of the organizations involved with the program, including their contact information. It lists all the materials that are available to the reader, along with an order code number.
Users also downloaded
Showing related downloaded files
No results found.